References
- Goldschmidt N, Darawshy F, Kleinstern G, et al. The prognostic value of bone marrow involvement at the molecular level in aggressive lymphoma. Leuk Lymph. 2017;58:45–52.
- Cerci JJ, Gyorke T, Fanti S, et al. Combined PET and biopsy evidence of marrow involvement improves prognostic prediction in diffuse large B-cell lymphoma. J Nucl Med. 2014;55:1591–1597.
- Alzahrani M, El-Galaly TC, Hutchings M, et al. The value of routine bone marrow biopsy in patients with diffuse large B-cell lymphoma staged with PET/CT: a Danish–Canadian study. Ann Oncol. 2016;27:1095–1099.
- Adams HJ, Kwee TC, de Keizer B, et al. FDG PET/CT for the detection of bone marrow involvement in diffuse large B-cell lymphoma: systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2014;41:565–574.
- Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059–3068.
- Zelenetz AD, Gordon LI, Wierda WG, et al. Diffuse large B-cell lymphoma version 1. 2016. J Natl Compr Canc Netw. 2016;14:196–231.
- Schmitz N, Zeynalova S, Nickelsen M, et al. CNS International Prognostic Index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated With R-CHOP. J Clin Oncol. 2016;34:3150–3156.
- Sehn LH, Scott DW, Chhanabhai M, et al. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol. 2011;29:1452–1457.